StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences total Liver Disease Franchise Product Sales ($M) ($M)

Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary

QuarterlyAnnual
Latest, FY2025
3,217
Period ended Dec 31, 2025
Change on a year earlier
+6.5%
3,021 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Liver Disease Franchise Product Sales ($M) ($M)Year on yearSource
FY2025Dec 31, 20253,217+6.5%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 20243,021+8.5%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 20232,784-0.5%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 20222,798-1.8%Form 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 20212,850–Form 10-K (filed 2024-02-23) ↗

Breakdown

What makes up total liver disease franchise product sales ($m)

Cite this data

StockData. (2026). Gilead Sciences Total Liver Disease Franchise Product Sales ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_total

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.